These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 8475364)

  • 1. [Concerning:"Moderate Paget's disease treated with pamidronate (ADP): experience in 43 patients with a single 60 mg perfusion of various duration of 1-to-24 hours" by D. Thièbaud at al. (Schweiz. med. Wschr. 1992; 122:1889-1894)].
    Staehelin-Bosshard A
    Schweiz Med Wochenschr; 1993 Mar; 123(12):554-5. PubMed ID: 8475364
    [No Abstract]   [Full Text] [Related]  

  • 2. Pamidronate for Paget's disease of the bone.
    Crisp AJ
    Br J Hosp Med; 1995 Feb 1-14; 53(3):66-8. PubMed ID: 7728317
    [No Abstract]   [Full Text] [Related]  

  • 3. Perspectives: a practical guide to the use of pamidronate in the treatment of Paget's disease.
    Siris ES
    J Bone Miner Res; 1994 Mar; 9(3):303-4. PubMed ID: 8191921
    [No Abstract]   [Full Text] [Related]  

  • 4. Pamidronate in the treatment of Paget's disease.
    Selby PL
    Bone; 1999 May; 24(5 Suppl):57S-58S. PubMed ID: 10321930
    [No Abstract]   [Full Text] [Related]  

  • 5. Osteomalacia after pamidronate for Paget's disease.
    Reid IR; Cundy T; Ibbertson HK; King AR
    Lancet; 1994 Apr; 343(8901):855. PubMed ID: 7908098
    [No Abstract]   [Full Text] [Related]  

  • 6. Moderate Paget's disease treated with pamidronate: comparison of various infusion rates for a 60-mg single dose.
    Thiebaud D; Portmann L; Burckhardt P
    Semin Arthritis Rheum; 1994 Feb; 23(4):279. PubMed ID: 8009257
    [No Abstract]   [Full Text] [Related]  

  • 7. Mineralisation defects with pamidronate therapy for Paget's disease.
    Adamson BB; Gallacher SJ; Byars J; Ralston SH; Boyle IT; Boyce BF
    Lancet; 1993 Dec; 342(8885):1459-60. PubMed ID: 7902484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Paget's disease of bone with single-dose intravenous pamidronate.
    Watts RA; Skingle S; Bhambani M; Pountain G; Crisp AJ
    Semin Arthritis Rheum; 1994 Feb; 23(4):281. PubMed ID: 8009259
    [No Abstract]   [Full Text] [Related]  

  • 9. Ototoxicity associated with intravenous bisphosphonate administration.
    Reid IR; Mills DA; Wattie DJ
    Calcif Tissue Int; 1995 Jun; 56(6):584-5. PubMed ID: 7648491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-dose intravenous pamidronate is effective alternative therapy for Paget's disease refractory to calcitonin.
    Yap AS; Mortimer RH; Jacobi JM; Galligan JP; Perry-Keene DA; Khafagi FA
    Horm Res; 1991; 36(1-2):70-4. PubMed ID: 1814803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Moderate Paget's disease treated with pamidronate (APD): experience in 43 patients with a single 60 mg infusion of varying duration of 1-to-24 hours].
    Thiébaud D; Portmann L; Burckhardt P
    Schweiz Med Wochenschr; 1992 Dec; 122(49):1889-94. PubMed ID: 1462150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone.
    Walsh JP; Ward LC; Stewart GO; Will RK; Criddle RA; Prince RL; Stuckey BG; Dhaliwal SS; Bhagat CI; Retallack RW; Kent GN; Drury PJ; Vasikaran S; Gutteridge DH
    Bone; 2004 Apr; 34(4):747-54. PubMed ID: 15050907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Paget's disease of bone.
    Anderson D; Cantrill JC
    Br Med J (Clin Res Ed); 1988 Jan; 296(6617):291. PubMed ID: 3124919
    [No Abstract]   [Full Text] [Related]  

  • 14. Oral pamidronate in refractory Paget's disease.
    Roldán EJ
    Calcif Tissue Int; 1994 Sep; 55(3):240. PubMed ID: 7864963
    [No Abstract]   [Full Text] [Related]  

  • 15. Pamidronate and Paget's disease.
    Anderson DC; Richardson PC
    Lancet; 1994 Feb; 343(8894):427. PubMed ID: 7905589
    [No Abstract]   [Full Text] [Related]  

  • 16. Disodium pamidronate has beneficial effect in Paget's disease of bone.
    Chakravarty K; Merry P; Scott DG
    BMJ; 1996 Jun; 312(7044):1476-7. PubMed ID: 8664641
    [No Abstract]   [Full Text] [Related]  

  • 17. Paget's disease--five years follow up after pamidronate therapy.
    Ryan PJ; Fogelman I
    Br J Rheumatol; 1994 Jan; 33(1):98-9. PubMed ID: 8162470
    [No Abstract]   [Full Text] [Related]  

  • 18. New drugs for Paget's disease.
    Anderson DC; Buckler HM; Cantrill JA
    Lancet; 1986 Jun; 1(8495):1442. PubMed ID: 2872541
    [No Abstract]   [Full Text] [Related]  

  • 19. Mineralisation defects after pamidronate for Paget's disease.
    Boyce BF; Adamson BB; Gallacher SJ; Byars J; Ralston SH; Boyle IT
    Lancet; 1994 May; 343(8907):1231-2. PubMed ID: 7909901
    [No Abstract]   [Full Text] [Related]  

  • 20. Bisphosphonates and Paget's disease.
    Bijvoet OL; Reitsma PH; Frijlink WB
    Lancet; 1980 Jun; 1(8183):1416-7. PubMed ID: 6104199
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.